To the Editor We read with interest the recent article by Calomarde-Rees et al1 on risk factors for lymphatic and hematogenous dissemination in patients with stage I and II melanoma. We agree that an improved understanding of the clinicopathological and mutation factors that relate to lymphatic and hematogenous dissemination is important to individualize surveillance strategies.